(2,3-di-O-acetyl-6-O-tert-butyldimethylsilyl)hexakis(2,3,6-tri-O-acetyl)cyclomaltoheptaose | 116525-06-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2,3-di-O-acetyl-6-O-tert-butyldimethylsilyl)hexakis(2,3,6-tri-O-acetyl)cyclomaltoheptaose
• 英文别名: [(1R,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36S,37R,38S,39R,40S,41R,42S,43R,44S,45R,46S,47R,48S,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecaacetyloxy-10,15,20,30,35-pentakis(acetyloxymethyl)-25-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methyl acetate
• CAS: 116525-06-5
• 化学式: C₈₈H₁₂₄O₅₅Si
• 分子量: 2090.01
• InChiKey: LBURRTIBKZNSHI-HSDPJANRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.79
• 重原子数：
  144.0
• 可旋转键数：
  29.0
• 环数：
  21.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  664.45
• 氢给体数：
  0.0
• 氢受体数：
  55.0

反应信息

• 作为反应物：
  描述：

  (2,3-di-O-acetyl-6-O-tert-butyldimethylsilyl)hexakis(2,3,6-tri-O-acetyl)cyclomaltoheptaose 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 1.5h， 以57.2%的产率得到(2,3-di-O-acetyl)hexakis(2,3,6-tri-O-acetyl)cyclomaltoheptaose
  参考文献：
  名称：

  6-O-α-d-吡喃葡萄糖基环麦芽庚糖的合成

  摘要：

  摘要通过将环麦芽庚糖与叔丁基二甲基甲硅烷基氯在吡啶中反应，然后进行乙酰化和去甲硅烷基化反应，制得（2,3-二-O-乙酰基）六（2,3,6-三-O-乙酰基）环麦芽九糖。使用三氟甲磺酸作为催化剂，用2,3,4,6-四-O-苄基-1-O-三氯乙酰亚胺基-α-d-吡喃葡萄糖进行糖基化，然后从产物中除去保护基，得到标题化合物。

  DOI：

  10.1016/0008-6215(88)84140-5
• 作为产物：
  描述：

  β-环糊精 、 叔丁基二甲基氯硅烷 生成 (2,3-di-O-acetyl-6-O-tert-butyldimethylsilyl)hexakis(2,3,6-tri-O-acetyl)cyclomaltoheptaose
  参考文献：
  名称：

  FUGEDI, PETER;NANASI, PAL;SZEJTLI, JOZSEF, CARBOHYDR. RES., 175,(1988) N 2, 173-181

  摘要：

  DOI：

文献信息

• Synthesis and Drug Complexation Studies with β-Cyclodextrins Fluorinated on the Primary Face
  作者：J. Diakur、Z. Zuo、L. I. Wiebe

  DOI：10.1080/07328309908543991

  日期：1999.1.1

  Three fluorinated beta-cyclodextrin derivatives, namely 5, 9 and 12, were prepared with the hope that the fluorine reporter group may assist in direct evaluation of the complexation properties of these potential drug carriers. Two of the synthesized derivatives, the previously reported monofluoro-beta-cyclodextrin 9 and the novel trifluoroethylthio-beta-cyclodextrin 12, displayed reasonable aqueous solubility and thus were suitable for drug-cyclodextrin complexation studies. Preliminary NMR results (H-1 and F-19) on the host-guest complex formation of both of these cyclodextrin derivatives with amantidine, a therapeutic agent employed in the treatment of Influenza A infections, are also presented.